evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

668 questions · 685 findings · 68 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 181 · 26.4%GRADE not reported 16 · 2.3%Very low 151 · 22%Low 211 · 30.8%Moderate 98 · 14.3%High 28 · 4.1%

Higher‐dose vs lower‐dose nicotine patch

Smoking cessation · people who smoke

Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).

3 findings from 1 review

Higher‐dose vs lower‐dose nicotine patch

SAEs · people who smoke

Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).

2 findings from 1 review

Higher‐dose vs lower‐dose nicotine patch

Treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) · people who smoke

Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).

1 finding from 1 review

Intravenous tranexamic acid vs placebo

Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes risk of myocardial infarction (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

The review found no eligible studies for this question.

1 finding from 1 review